Nausea and vomiting are among the common side effects of GLP-1 drugs reported in clinical trials. To understand whether their frequency differs by sex, it helps to distinguish symptoms collected in clinical trials from diagnoses entered in routine medical records.
What did the tirzepatide records study find?
Researchers matched 1,654 men with 1,654 women taking tirzepatide. All had obesity and heart failure with preserved ejection fraction (HFpEF). Nausea and vomiting were recorded in 3.8% of men and 7.9% of women, with an estimated hazard ratio of 0.50. For diarrhea the hazard ratio was 0.84 (95% CI 0.59 to 1.19), an inconclusive difference [1].
The study compared people who were already taking tirzepatide. It did not establish how much the drug itself contributes to the difference, and electronic records can miss symptoms that patients or clinicians do not document.
What did clinical trials report by sex?
A post hoc analysis of the SURPASS type 2 diabetes trials reported gastrointestinal adverse events by sex and other baseline factors. Digestive symptoms occurred in both sex groups. Estimates can vary across trials, doses and comparators. Eli Lilly funded the subgroup analysis [2].
The U.S. Wegovy label provides another example. In three pooled studies, hair loss was reported in 4% of female and 0.9% of male participants receiving 2.4 mg injections, versus 2% and 0% with placebo, respectively [3]. The same label reports sex-specific data on hip and pelvic fractures in the cardiovascular trial, a different outcome studied in a different patient population. These findings do not give a single prediction for all GLP-1 medicines.